Human T cell responses to ESAT-6 and eight synthetic overlapping peptides were investigated
in tuberculosis (TB) patients and control subjects from regions of high and low endemicity …

The lack of defined correlates of protection hampers development of vaccines against
tuberculosis (TB). In vitro mycobacterial outgrowth assays are thought to better capture the …

Proteins encoded by DNA segment RD1 of Mycobacterium tuberculosis have recently been
demonstrated to play important roles in bacterial virulence, vaccine development, and …

More than 2 billion individuals are latently infected with Mycobacterium tuberculosis (Mtb).
Knowledge of the key Mtb antigens and responding T‐cell subsets mediating protection …

A nasal vaccine, consisting of outer membrane vesicles (OMVs) from group B Neisseria
meningitidis, was given to 12 volunteers in the form of nose drops or nasal spray four times at …

Mycobacterium tuberculosis is responsible for almost 2 million deaths annually. Mycobacterium
bovis bacillus Calmette-Guérin, the only vaccine available against tuberculosis (TB), …

Introduction Targeted testing and treatment of latent TB infection (LTBI) are priorities on the
global health agenda, but LTBI management remains challenging. We aimed to evaluate the …

New strategies are needed to develop better tools to control TB, including identification of
novel antigens for vaccination. Such Mtb antigens must be expressed during Mtb infection in …

The Mycobacterium bovis BCG vaccine is the only tuberculosis (TB) vaccine available, yet it
provides limited protection against pulmonary TB in adults and fails to protect against TB …

We studied the secondary attack rate (SAR), risk factors, and precautionary practices of
household transmission in a prospective, longitudinal study. We further compared transmission …